Zacks Research Brokers Lower Earnings Estimates for Avantor

Key Points

• Zacks Research lowered its Q2 2026 EPS estimate for Avantor to $0.19 from $0.20 and reiterated a Hold rating on the stock.
• Avantor recently reported quarterly earnings of $0.17 per share, topping expectations, while revenue came in at $1.58 billion versus the $1.54 billion consensus.
• Analyst sentiment remains cautious overall, with Avantor carrying an average Hold rating and a consensus target price of $10.82, while the stock traded at $7.87 in Thursday’s session.

Avantor, Inc. (NYSE:AVTR - Free Report) - Research analysts at Zacks Research lowered their Q2 2026 earnings per share estimates for shares of Avantor in a research note issued to investors on Wednesday, May 20th. Zacks Research analyst Team now anticipates that the company will earn $0.19 per share for the quarter, down from their previous estimate of $0.20. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Avantor's current full-year earnings is $0.79 per share. Zacks Research also issued estimates for Avantor's Q3 2026 earnings at $0.20 EPS, FY2026 earnings at $0.78 EPS, Q1 2027 earnings at $0.19 EPS, Q1 2028 earnings at $0.22 EPS and FY2028 earnings at $0.91 EPS.

Avantor (NYSE:AVTR - Get Free Report) last released its earnings results on Wednesday, April 29th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.16 by $0.01. The company had revenue of $1.58 billion for the quarter, compared to analysts' expectations of $1.54 billion. Avantor had a positive return on equity of 9.95% and a negative net margin of 8.42%.The business's revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.23 EPS.

A number of other equities research analysts also recently issued reports on AVTR. Robert W. Baird set a $11.00 target price on shares of Avantor in a research report on Thursday, February 12th. TD Cowen reaffirmed a "hold" rating on shares of Avantor in a research note on Thursday, February 12th. Stifel Nicolaus set a $10.00 price objective on Avantor in a report on Thursday, February 12th. UBS Group reissued a "neutral" rating and set a $10.50 price objective on shares of Avantor in a research report on Thursday, February 12th. Finally, Citigroup lowered their target price on Avantor from $11.00 to $9.00 and set a "neutral" rating on the stock in a research note on Thursday, April 30th. Two analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Avantor currently has an average rating of "Hold" and a consensus target price of $10.82.

Avantor Stock Performance

Shares of AVTR opened at $7.87 on Thursday. The company's 50 day moving average price is $7.95 and its 200 day moving average price is $9.91. Avantor has a 52 week low of $7.26 and a 52 week high of $15.93. The company has a market capitalization of $5.37 billion, a PE ratio of -9.71, a PEG ratio of 4.41 and a beta of 0.94. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.17 and a current ratio of 1.76.

Institutional Trading of Avantor

A number of institutional investors and hedge funds have recently made changes to their positions in AVTR. Dodge & Cox increased its holdings in shares of Avantor by 0.3% during the 3rd quarter. Dodge & Cox now owns 117,746,888 shares of the company's stock valued at $1,469,481,000 after acquiring an additional 313,404 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Avantor by 1.8% in the 3rd quarter. Vanguard Group Inc. now owns 65,988,977 shares of the company's stock worth $823,542,000 after purchasing an additional 1,135,279 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC boosted its position in Avantor by 10.8% during the third quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 34,548,129 shares of the company's stock worth $431,161,000 after purchasing an additional 3,356,861 shares during the period. Wellington Management Group LLP bought a new stake in Avantor during the fourth quarter worth approximately $268,584,000. Finally, Greenhaven Associates Inc. grew its holdings in Avantor by 12.0% during the fourth quarter. Greenhaven Associates Inc. now owns 20,500,653 shares of the company's stock valued at $234,937,000 after purchasing an additional 2,189,083 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company's stock.

Insider Transactions at Avantor

In other Avantor news, Director Gregory T. Lucier purchased 10,000 shares of the business's stock in a transaction dated Friday, May 8th. The shares were acquired at an average price of $8.32 per share, for a total transaction of $83,200.00. Following the acquisition, the director owned 60,000 shares of the company's stock, valued at $499,200. This trade represents a 20.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Sanjeev K. Mehra acquired 125,000 shares of Avantor stock in a transaction that occurred on Tuesday, March 10th. The stock was acquired at an average cost of $8.01 per share, with a total value of $1,001,250.00. Following the purchase, the director owned 475,000 shares in the company, valued at $3,804,750. The trade was a 35.71% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 160,000 shares of company stock worth $1,287,950 in the last 90 days. 0.28% of the stock is owned by insiders.

Avantor Company Profile

Avantor, Inc NYSE: AVTR is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company delivers essential solutions that support research, development, production and safety applications. Its product portfolio spans from high-purity chemicals and reagents to biologics and cell culture media, as well as lab equipment, consumables and custom manufacturing services.

Avantor's offerings are organized across two primary segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.